Another link back and my point, which I was saving.... I think Gilead will fall into this category below as "Sometimes the people with the most experience don't see what is right in front of them." Now, we are coming after combo, and mono, and prep, and cancer, and nash, and cv. They could have partnered for measly millions + half revenue. I suspect they wanted their standard 80% cut. I know NP has met with them over the years, as he has mentioned talking to their executives and commented about what they told him. They could have bought out cydy years ago for pennys, but they couldn't see, they were blind. All the experience in the world and no foresight. Well except for that one Gilead analyst, who they apparently choose to ignore. All imo.
Quote:
Sometimes the people with the most experience don't see what is right in front of them
Read More: https://investorshangout.com/post/postreplies...z6HvweLAYT